Adma Biologics Overview
Valuation check: ADMA's PEG ratio is 123.2, above the Healthcare sector average of 2.56.
Get informed when a big investor buys or sells
+ Follow123.20
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for ADMA is 123.2. That is above the Healthcare sector average of 2.56. Investors often review this figure alongside Adma Biologics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ADMA currently prints 123.2 for PEG ratio, while the sector average sits near 2.56. That is roughly 4713.1% above the sector mean. Large gaps often invite a closer look at Adma Biologics's growth, margins, and balance sheet.
A PEG ratio of 123.2 for Adma Biologics is not 'good' or 'bad' on its own. Compare it with the peer average (2.56) and with ADMA's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ADMA's PEG ratio (123.2), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Adma Biologics's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
